The Molecular Organization of Human cGMP Specific Phosphodiesterase 6 (PDE6): Structural Implications of Somatic Mutations in Cancer and Retinitis Pigmentosa

[1]  A. Sali,et al.  Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.

[2]  Douglas E. V. Pires,et al.  DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach , 2014, Nucleic Acids Res..

[3]  P. Comtois,et al.  PDE6 Isoforms Are Expressed in Native Endothelium but not in Cultured Cell Lines , 2016 .

[4]  B. J. Klevering,et al.  High-resolution homozygosity mapping is a powerful tool to detect novel mutations causative of autosomal recessive RP in the Dutch population. , 2011, Investigative ophthalmology & visual science.

[5]  Tom L. Blundell,et al.  SDM: a server for predicting effects of mutations on protein stability , 2017, Nucleic Acids Res..

[6]  Shahbaz Ali,et al.  Splice-site mutations identified in PDE6A responsible for retinitis pigmentosa in consanguineous Pakistani families , 2015, Molecular vision.

[7]  J. Beavo,et al.  The Structure of the GAF A Domain from Phosphodiesterase 6C Reveals Determinants of cGMP Binding, a Conserved Binding Surface, and a Large cGMP-dependent Conformational Change*♦ , 2008, Journal of Biological Chemistry.

[8]  N. Artemyev.  G-Protein–Effector Coupling in the Vertebrate Phototransduction Cascade , 2014 .

[9]  K. Mizuguchi,et al.  An iterative structure‐assisted approach to sequence alignment and comparative modeling , 1999, Proteins.

[10]  T L Blundell,et al.  FUGUE: sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties. , 2001, Journal of molecular biology.

[11]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[12]  Kam Y. J. Zhang,et al.  A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. , 2004, Molecular cell.

[13]  O. Torres-Quesada,et al.  The many faces of compartmentalized PKA signalosomes. , 2017, Cellular signalling.

[14]  A. Dinculescu,et al.  Review: The history and role of naturally occurring mouse models with Pde6b mutations , 2013, Molecular vision.

[15]  D. Schadendorf,et al.  cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells , 2009, Cellular and Molecular Life Sciences.

[16]  David F. Burke,et al.  Andante: reducing side-chain rotamer search space during comparative modeling using environment-specific substitution probabilities , 2007, Bioinform..

[17]  E. Degerman,et al.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. , 2015, Oral diseases.

[18]  A. D. den Hollander,et al.  Homozygosity Mapping and Targeted Sanger Sequencing Reveal Genetic Defects Underlying Inherited Retinal Disease in Families from Pakistan , 2015, PloS one.

[19]  S. Beck,et al.  Retinitis pigmentosa: impact of different Pde6a point mutations on the disease phenotype. , 2015, Human molecular genetics.

[20]  Charlotte M. Deane,et al.  JOY: protein sequence-structure representation and analysis , 1998, Bioinform..

[21]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[22]  T. Dryja,et al.  Frequency of mutations in the gene encoding the alpha subunit of rod cGMP-phosphodiesterase in autosomal recessive retinitis pigmentosa. , 1999, Investigative ophthalmology & visual science.

[23]  R. Cantor,et al.  Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response , 2006, Proceedings of the National Academy of Sciences.

[24]  Douglas E. V. Pires,et al.  mCSM: predicting the effects of mutations in proteins using graph-based signatures , 2013, Bioinform..

[25]  L. Gakhar,et al.  Structural basis of phosphodiesterase 6 inhibition by the C‐terminal region of the γ‐subunit , 2009, The EMBO journal.

[26]  J. Corbin,et al.  cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action , 2010, Pharmacological Reviews.

[27]  P. Sieving,et al.  Mutations in the gene encoding the alpha-subunit of rod phosphodiesterase in consanguineous Pakistani families. , 2006, Molecular vision.

[28]  T. Burdyga,et al.  Evidence that NO/cGMP/PKG signalling cascade mediates endothelium dependent inhibition of IP3R mediated Ca2+ oscillations in myocytes and pericytes of ureteric microvascular network in situ , 2015, Cell calcium.

[29]  Shibing Deng,et al.  OASIS: web-based platform for exploring cancer multi-omics data , 2015, Nature Methods.

[30]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[31]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[32]  K. Palczewski,et al.  Structural characterization of the rod cGMP phosphodiesterase 6. , 2010, Journal of molecular biology.

[33]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[34]  E. Zrenner,et al.  Efficacy of PARP inhibition in Pde6a mutant mouse models for retinitis pigmentosa depends on the quality and composition of individual human mutations , 2016, Cell Death Discovery.

[35]  Li Ma,et al.  Suppression of Cyclic GMP-dependent Protein Kinase Is Essential to the Wnt/cGMP/Ca2+ Pathway* , 2006, Journal of Biological Chemistry.

[36]  K. Fennell,et al.  Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct , 2009, Proceedings of the National Academy of Sciences.

[37]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[38]  C. Lugnier,et al.  Expression and role of phosphodiesterase 6 in the chicken pineal gland , 2001, Journal of neurochemistry.

[39]  D M Essayan,et al.  Cyclic nucleotide phosphodiesterases. , 2001, The Journal of allergy and clinical immunology.

[40]  Q. Ding,et al.  Targeting stem cell signaling pathways for drug discovery: advances in the Notch and Wnt pathways , 2014, Science China Life Sciences.

[41]  T. Rosenberg,et al.  Heterozygous missense mutation in the rod cGMP phosphodiesterase β–subunit gene in autosomal dominant stationary night blindness , 1994, Nature Genetics.

[42]  R. Zoraghi,et al.  Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. , 2007, Biochemistry.

[43]  M. Snyder,et al.  Systematic investigation of protein–small molecule interactions , 2013, IUBMB life.

[44]  M. Karplus,et al.  Evaluation of comparative protein modeling by MODELLER , 1995, Proteins.

[45]  J. Corbin,et al.  Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. , 2011, Physiological reviews.

[46]  M. White,et al.  Signaling Pathways: The Benefits of Good Communication , 2004, Current Biology.

[47]  K. Claffey,et al.  Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells , 2013, SpringerPlus.

[48]  P. Schultz,et al.  Molecular organization of bovine rod cGMP-phosphodiesterase 6. , 2001, Journal of molecular biology.

[49]  T. Pawson,et al.  Cell Signaling in Space and Time: Where Proteins Come Together and When They’re Apart , 2009, Science.

[50]  S. Babykutty,et al.  Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways , 2012, Clinical & Experimental Metastasis.

[51]  S. Ferrari,et al.  Retinitis Pigmentosa: Genes and Disease Mechanisms , 2011, Current genomics.

[52]  H. Ke,et al.  Conformation Changes, N-terminal Involvement, and cGMP Signal Relay in the Phosphodiesterase-5 GAF Domain* , 2010, The Journal of Biological Chemistry.

[53]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[54]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[55]  D. Schadendorf,et al.  Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model , 2011, Proceedings of the National Academy of Sciences.

[56]  M. Conti.  Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. , 2000, Molecular endocrinology.

[57]  P. S. Klein,et al.  Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. , 1997, Developmental biology.

[58]  E. Peschke,et al.  Involvement of the cGMP pathway in mediating the insulin‐inhibitory effect of melatonin in pancreatic β‐cells , 2008, Journal of pineal research.

[59]  J. Bennett,et al.  Dark-rearing the rd10 mouse: implications for therapy. , 2012, Advances in experimental medicine and biology.

[60]  J. Beavo,et al.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.